Published by
The Street
The Street
By Maxx Chatsko Cash rules everything around the diagnostics leader, which pledged to prioritize profitable growth. Cancer diagnostics powerhouse Exact Sciences (EXAS) – Get Exact Sciences Corporation Report appears on track to easily beat full-year 2022 revenue guidance. Despite the trend through the first half of the year, management opted to maintain guidance set in May. That prompted a few questions from analysts on the conference call to discuss second-quarter 2022 operating results. “Why the conservatism?,” asked one analyst. Management had a simple reply: “Cash rules everything around m…
Share this Story